Introduction
In late (December) 2019 a new pneumonia with unknown origin, detected in
patients who were linked to a seafood wholesale market, where wild
animals were illegally sold in china. After testing the specimens of the
patient’s airway epithelial cells, a novel coronavirus was detected and
described as 2019-nCov, and was later named severe acute respiratory
syndrome coronavirus 2 (SARS-COV-2) by WHO, and the disease caused by
this new virus, was named Covid-19 (Zhu et al., 2020).
This new virus is the seventh human coronavirus described to date as
being responsible for respiratory infections (Devaux, Rolain, Colson, &
Raoult, 2020), and categorized in the Betacoronaviruse subgroup(Zhu et
al., 2020).
Covid-19 rapidly spread in the world and made an unprecedented pandemic
on March 12, 2020, became a big concern for global health with
threatening public health over the world. Thus there was an urgent need
for an effective treatment and conducting clinical trials and studies
for assessing the efficacy of different repurposed drugs for treatment
and prevention of transmission of this infection (Kupferschmidt &
Cohen, 2020). So WHO considered a Solidarity and a major study, on March
20, 2020 to collect scientific data and compare therapeutic strategies
for defining an effective treatment for patients with Covid-19, wants
the hospitals overwhelmed by Covid-19 patients to participate, and from
the physicians to simply record their results as the duration of
hospital stay, whether the patients required intensive care unit (ICU)
admission or ventilation and the day patient left the hospital or died.
”That’s all” says Ana Maria Henao
Restrepo, a medical officer at WHO’s Emergencies Programme
(Kupferschmidt & Cohen, 2020).
There for we decided to do our duty in this Solidarity and describe the
result of our therapeutic regimens in this hospital, as a center for
Covid-19 patients.
Antiviral drugs, may be the best
candidates for the treatment of Covid-19, until we have specific
therapeutic drugs (Kivrak, Ulaş, & Kivrak, 2021). Oseltamivir (brand
name Tamiflu) is a neuraminidase inhibitor that is approved for
treatment and prophylaxis of influenza A and B ((Yousefi, Mashouri,
Okpechi, Alahari, & Alahari, 2021),(Agrawal, Goel, & Gupta, 2020)).It
can inhibit the spread of the influenza virus and reduce viral shedding
in respiratory secretions in the human body (Agrawal et al., 2020), and
is considered as a therapeutic option in several clinical trials and
studies but the results remain controversial ((Zhou et al.,
2020),(Ungogo, Mohammed, Umar, Bala, & Khalid, 2021)). There for
further studies are required to demonstrate the efficacy of antiviral
drugs for the treatment of Covid-19 patients.
In this study we aimed to evaluate the efficacy of Oseltamivir, by
comparing two different combination therapeutic regimens, based on
length of hospital stay, need for ICU admission, mechanical ventialation
and mortality rate.